Skip to main content
TipRanks
Go Ultimate75% OFF

Ikonisys SA (9W8) AI Stock Analysis

0 Followers
DE:9W8

Ikonisys SA

(Frankfurt:9W8)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue GrowthSharp revenue acceleration indicates stronger commercial adoption of the company’s oncology testing solutions and expanding market activity. If sustained, this growth can improve operating leverage, support reinvestment in the platform, and strengthen the company’s position over the next several quarters.
Negative Factors
Persistent LossesVery large and worsening losses show that revenue growth has not yet translated into operating leverage or sustainable earnings. Continued losses can erode the equity base, restrict internal funding capacity, and make the company’s longer-term financial model dependent on a successful profitability transition.

Ikonisys SA (9W8) vs. iShares MSCI Germany ETF (EWG)

-10%-5%0%5%10%15%20%25%30%DE:9W8+1.87%EWG+9.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 23.05M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-5.3
Beta (1Y)
0.07
Revenue Growth
37.28%
EPS Growth
7.83%
Country
Germany
Employees
15
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Ikonisys SA Business Overview & Revenue Model

Company Description

Based in Paris, France, Ikonisys S.A. is a company specializing in cell-based diagnostics. It develops, produces, and commercializes medical diagnostic solutions for various cancers across the United States and Europe. Their core offering includes th...

Ikonisys SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:9W8 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
FR:ALERSFR:ALERS58NeutralEUR 258.89M37.643.89%―6.28%204.56%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FR:ALMKTFR:ALMKT45NeutralEUR 17.81M1.44-157.72%―3.38%―
FR:ALNOVFR:ALNOV45NeutralEUR 32.66M-0.78-159.70%―10.36%29.41%
FR:ALMDTFR:ALMDT43NeutralEUR 209.76M-3.48271.64%―2.16%-5.26%

* Healthcare Sector Average

Performance Comparison

0%50%100%150%DE:9W8FR:ALMKTFR:ALNOVFR:ALERSFR:ALDMSFR:ALMDTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:9W8 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:9W8Ikonisys SA1.360.021.12%
FR:ALMKTMAUNA KEA TECHNOLOGIES0.090.0110.98%
FR:ALNOVNovacyt S.A.0.450.023.45%
FR:ALERSEurobio-Scientific SA26.352.209.11%
FR:ALDMSDiagnostic Medical Systems0.91-0.36-28.19%
FR:ALMDTMedian Technologies4.281.3545.83%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.